Modulation of circulatory residence of recombinant acetylcholinesterase through biochemical or genetic manipulation of sialylation levels
Open Access
- 15 December 1998
- journal article
- research article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 336 (3) , 647-658
- https://doi.org/10.1042/bj3360647
Abstract
Sialylation of N-glycans associated with recombinant human acetylcholinesterase (rHuAChE) has a central role in determining its circulatory clearance rate. Human embryonal kidney 293 (HEK-293) cells, which are widely used for the expression of recombinant proteins, seem to be limited in their ability to sialylate overexpressed rHuAChE. High-resolution N-glycan structural analysis, by gel permeation, HPLC anion-exchange chromatography and high-pH anion-exchange chromatography (HPAEC), revealed that the N-glycans associated with rHuAChE produced in HEK-293 cells belong mainly to the complex-biantennary class and are only partly sialylated, with approx. 60% of the glycans being monosialylated. This partial sialylation characterizes rHuAChE produced by cells selected for high-level expression of the recombinant protein. In low-level producer lines, the enzyme exhibits a higher sialic acid content, suggesting that undersialylation of rHuAChE in high-level producer lines stems from a limited endogenous glycosyltransferase activity. To improve sialylation in HEK-293 cells, rat liver β-galactoside α-2,6-sialyltransferase cDNA was stably transfected into cells expressing high levels of rHuAChE. rHuAChE produced by the modified cells displayed a significantly higher proportion of fully sialylated glycans as shown by sialic acid incorporation assays, direct measurement of sialic acid, and HPAEC glycan profiling. Genetically modified sialylated rHuAChE exhibited increased circulatory retention (the slow-phase half-life, t½β, was 130 min, compared with 80 min for the undersialylated enzyme). Interestingly, the same increase in circulatory residence was observed when rHuAChE was subjected to extensive sialylation in vitro. The engineered HEK-293 cells in which the glycosylation machinery was modified might represent a valuable tool for the high level of expression of recombinant glycoproteins whose sialic acid content is important for their function or for pharmacokinetic behaviour.Keywords
This publication has 44 references indexed in Scilit:
- Role of Oligosaccharides in the Pharmacokinetics of Tissue-Derived and Genetically Engineered CholinesterasesMolecular Pharmacology, 1998
- Structure of Glycan Moieties Responsible for the Extended Circulatory Life Time of Fetal Bovine Serum Acetylcholinesterase and Equine Serum ButyrylcholinesteraseBiochemistry, 1997
- A mathematical model of sialylation of N-linked oligosaccharides in the trans-Golgi network.Glycobiology, 1997
- Differential recognition of glycoprotein acceptors by terminal glycosyltransferasesGlycobiology, 1997
- Two Naturally Occurring α2,6-Sialyltransferase Forms with a Single Amino Acid Change in the Catalytic Domain Differ in Their Catalytic Activity and Proteolytic ProcessingJournal of Biological Chemistry, 1997
- Aging of phosphylated human acetylcholinesterase: catalytic processes mediated by aromatic and polar residues of the active centreBiochemical Journal, 1996
- The Architecture of Human Acetylcholinesterase Active Center Probed by Interactions with Selected Organophosphate InhibitorsPublished by Elsevier ,1996
- Involvement of oligomerization, N-glycosylation and sialylation in the clearance of cholinesterases from the circulationBiochemical Journal, 1995
- Two Receptor Systems Are Involved in the Plasma Clearance of Tissue Factor Pathway Inhibitor in VivoJournal of Biological Chemistry, 1995
- Primary structure of beta-galactoside alpha 2,6-sialyltransferase. Conversion of membrane-bound enzyme to soluble forms by cleavage of the NH2-terminal signal anchor.Journal of Biological Chemistry, 1987